Latest press releases

The story of

TreeFrog Therapeutics


Cell therapy for all

Incorporated in Bordeaux in 2018, TreeFrog Therapeutics is a French-based biotech startup aimed at making cell therapies safer, more efficient, more accessible and more affordable for millions of patients.



The C-Stem™ technology introduces:

  • A highly scalable manufacturing process allowing for the mass production of cell therapies based on induced pluripotent stem cells (iPSC), while drastically reducing costs.

  • A new quality standard for iPSC-derived cell therapy products

  • A 3D transplantation format enhancing therapeutic outcomes

Going for mass market

TreeFrog is advancing a pipeline of cell therapies targeting high-burden and currently incurable chronic and degenerative diseases, including blood and immune disorders, Parkinson’s disease, and heart failure.
Key figures
meeting in Geneva

TreeFrog Therapeutics was co-founded by Kevin Alessandri, PhD, an expert in 3D-printed microfluidics, and Maxime Feyeux, a stem cell biologist who was one of first PhD students worldwide to work on pluripotent stem cells.

$ 0 M
raised since inc. in 2018

Awarded with top innovation grants at French & European level (i-LAB, i-Nov, EIC accelerator), TreeFrog also attracted over $15M in private investments over the past 3 years.

0 +
froggies in Bordeaux

Bringing together physicists, cell biologists and bioproduction engineers
self-dubbed the froggies, the TreeFrog team will grow 3-fold over the next 3 years, expanding in France,  USA and Japan.

0 +
ongoing contracts

Focused on bringing the benefits of C-Stem™ as fast as possible to patients, TreeFrog is partnering with market leaders in EU, USA and Japan to develop cell therapies with mass-market potential.

The latest

They talked about us


Contact us !